[
  {
    "ts": null,
    "headline": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
    "summary": "Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.",
    "url": "https://finnhub.io/api/news?id=62dc2759f240cea1962b6f60cd16b18bc40e768baea3778f1df99db3cb10ea61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741638646,
      "headline": "Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out",
      "id": 133184496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.",
      "url": "https://finnhub.io/api/news?id=62dc2759f240cea1962b6f60cd16b18bc40e768baea3778f1df99db3cb10ea61"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?",
    "summary": "BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook for 2025 is weak. We recommend investors to wait.",
    "url": "https://finnhub.io/api/news?id=120da4bc06e851f73fede01cbf474ba725d930dc7944522928159892e4597a6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741633200,
      "headline": "Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?",
      "id": 133185686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook for 2025 is weak. We recommend investors to wait.",
      "url": "https://finnhub.io/api/news?id=120da4bc06e851f73fede01cbf474ba725d930dc7944522928159892e4597a6e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=350d9345cd56126c2892c2cd3558e25a261c8dabaeaa50f9181654aa566d36bf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741624620,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 133153120,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=350d9345cd56126c2892c2cd3558e25a261c8dabaeaa50f9181654aa566d36bf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now",
    "summary": "We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks have taken a backseat in the market as technology and AI-driven equities have soared to record highs. […]",
    "url": "https://finnhub.io/api/news?id=ba2a44e12ceb4754ba0e685f75c6665c87625e6d6a70c899b9dce3fe858d6dae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741617371,
      "headline": "Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now",
      "id": 133185687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend stocks. Dividend stocks have taken a backseat in the market as technology and AI-driven equities have soared to record highs. […]",
      "url": "https://finnhub.io/api/news?id=ba2a44e12ceb4754ba0e685f75c6665c87625e6d6a70c899b9dce3fe858d6dae"
    }
  },
  {
    "ts": null,
    "headline": "EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC",
    "summary": "The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.",
    "url": "https://finnhub.io/api/news?id=d0252c4a38225d10f0e7a43f33e1a1e616899b1c3645910ed0fa564bf753f6c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741614060,
      "headline": "EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC",
      "id": 133185688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.",
      "url": "https://finnhub.io/api/news?id=d0252c4a38225d10f0e7a43f33e1a1e616899b1c3645910ed0fa564bf753f6c2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu Compared With Placebo in Adults with Psoriatic Arthritis",
    "summary": "PRINCETON - Bristol Myers Squibb today announced positive data from the pivotal Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis...",
    "url": "https://finnhub.io/api/news?id=66a36be5e336a9f2416b9bda2e317fe8f644d3f726d3e817984ee1dc4d4dca95",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610291,
      "headline": "Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu Compared With Placebo in Adults with Psoriatic Arthritis",
      "id": 133122042,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced positive data from the pivotal Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis...",
      "url": "https://finnhub.io/api/news?id=66a36be5e336a9f2416b9bda2e317fe8f644d3f726d3e817984ee1dc4d4dca95"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
    "summary": "PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced...",
    "url": "https://finnhub.io/api/news?id=411deacc6b0d47f7a66ed7cb52e9c01b97473cd0ca63615e8f5535610a7aefbd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610241,
      "headline": "Bristol Myers Squibb Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
      "id": 133122033,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced...",
      "url": "https://finnhub.io/api/news?id=411deacc6b0d47f7a66ed7cb52e9c01b97473cd0ca63615e8f5535610a7aefbd"
    }
  },
  {
    "ts": null,
    "headline": "EC approves BMS’ Opdivo and Yervoy combo for HCC",
    "summary": "The approval is supported by positive outcomes from the open-label CheckMate -9DW trial.",
    "url": "https://finnhub.io/api/news?id=e897e884827c9a75d559cff7a715885fa7df6c0620fb9c41c3e6218143655ef9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741609959,
      "headline": "EC approves BMS’ Opdivo and Yervoy combo for HCC",
      "id": 133185689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The approval is supported by positive outcomes from the open-label CheckMate -9DW trial.",
      "url": "https://finnhub.io/api/news?id=e897e884827c9a75d559cff7a715885fa7df6c0620fb9c41c3e6218143655ef9"
    }
  },
  {
    "ts": null,
    "headline": "4 February Raises Includes AES Corporation's 6.2% Yield",
    "summary": "Rose's Income Garden achieved a near all-time high with a 5.9% yield. Learn why AES Corp and Mastercard are buys, while AbbVie and BMY are holds.",
    "url": "https://finnhub.io/api/news?id=0ae6ec35b38fca716fef829bcb0b98681e5669f59a5d8e4b85548afc64ed9cf8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741606641,
      "headline": "4 February Raises Includes AES Corporation's 6.2% Yield",
      "id": 133121732,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160750173/image_2160750173.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Rose's Income Garden achieved a near all-time high with a 5.9% yield. Learn why AES Corp and Mastercard are buys, while AbbVie and BMY are holds.",
      "url": "https://finnhub.io/api/news?id=0ae6ec35b38fca716fef829bcb0b98681e5669f59a5d8e4b85548afc64ed9cf8"
    }
  }
]